Logo image of REPH

RECRO PHARMA INC (REPH) Stock Fundamental Analysis

NASDAQ:REPH - Nasdaq - Common Stock

2.09  -0.01 (-0.48%)

After market: 2.09 0 (0%)

Fundamental Rating

1

REPH gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. REPH may be in some trouble as it scores bad on both profitability and health. REPH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year REPH has reported negative net income.
REPH Yearly Net Income VS EBIT VS OCF VS FCFREPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M -40M -60M

1.2 Ratios

Industry RankSector Rank
ROA -7.09%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
REPH Yearly ROA, ROE, ROICREPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 100 -100 200 300 400

1.3 Margins

Industry RankSector Rank
OM 0.55%
PM (TTM) -15.09%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
REPH Yearly Profit, Operating, Gross MarginsREPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -50 -100

More info and screens

2

2. Health

2.1 Basic Checks

REPH has more shares outstanding than it did 1 year ago.
The debt/assets ratio for REPH has been reduced compared to a year ago.
REPH Yearly Shares OutstandingREPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M
REPH Yearly Total Debt VS Total AssetsREPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -0.81, we must say that REPH is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of 2.27 is on the high side and indicates that REPH has dependencies on debt financing.
Industry RankSector Rank
Debt/Equity 2.27
Debt/FCF N/A
Altman-Z -0.81
ROIC/WACCN/A
WACCN/A
REPH Yearly LT Debt VS Equity VS FCFREPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M 100M

2.3 Liquidity

REPH has a Current Ratio of 3.24. This indicates that REPH is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 2.74 indicates that REPH has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 3.24
Quick Ratio 2.74
REPH Yearly Current Assets VS Current LiabilitesREPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 73.04% over the past year.
Looking at the last year, REPH shows a quite strong growth in Revenue. The Revenue has grown by 13.32% in the last year.
Measured over the past years, REPH shows a small growth in Revenue. The Revenue has been growing by 1.68% on average per year.
EPS 1Y (TTM)73.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.67%
Revenue 1Y (TTM)13.32%
Revenue growth 3Y-0.87%
Revenue growth 5Y1.68%
Sales Q2Q%125.06%

3.2 Future

REPH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.18% yearly.
Based on estimates for the next years, REPH will show a quite strong growth in Revenue. The Revenue will grow by 15.49% on average per year.
EPS Next Y5.68%
EPS Next 2Y10.01%
EPS Next 3Y4.51%
EPS Next 5Y1.18%
Revenue Next Year22.76%
Revenue Next 2Y15.97%
Revenue Next 3Y15.26%
Revenue Next 5Y15.49%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
REPH Yearly Revenue VS EstimatesREPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
REPH Yearly EPS VS EstimatesREPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for REPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for REPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
REPH Price Earnings VS Forward Price EarningsREPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 21.28
REPH Per share dataREPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.01%
EPS Next 3Y4.51%

More info and screens

0

5. Dividend

5.1 Amount

REPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RECRO PHARMA INC

NASDAQ:REPH (3/21/2022, 8:00:01 PM)

After market: 2.09 0 (0%)

2.09

-0.01 (-0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-01 2022-03-01/amc
Earnings (Next)05-04 2022-05-04
Inst Owners1.05%
Inst Owner Change0%
Ins Owners17.64%
Ins Owner Change0%
Market Cap97.56M
Analysts86.67
Price Target5.1 (144.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.29
P/FCF N/A
P/OCF N/A
P/B 2.32
P/tB N/A
EV/EBITDA 21.28
EPS(TTM)-0.31
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.61
BVpS0.9
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.09%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 0.55%
PM (TTM) -15.09%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.24
Quick Ratio 2.74
Altman-Z -0.81
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.67%
EPS Next Y5.68%
EPS Next 2Y10.01%
EPS Next 3Y4.51%
EPS Next 5Y1.18%
Revenue 1Y (TTM)13.32%
Revenue growth 3Y-0.87%
Revenue growth 5Y1.68%
Sales Q2Q%125.06%
Revenue Next Year22.76%
Revenue Next 2Y15.97%
Revenue Next 3Y15.26%
Revenue Next 5Y15.49%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A